Biomac Life Sciences is a translational research oriented biotech start-up company with
a primary focus on cell-based therapeutic technologies for unmet medical needs.
EXPERTS IN CELL BIOLOGY
We have team of experts in cell biology, cell therapy, gene editing, gene therapy, and have defined series of cell based therapeutic product pipeline to cure advanced cancers or life-threatening genetic disorders.
Read moreCURE BEYOND HOPE
Our vision is to bring evidence based cellular therapeutics in clinics to cure diseases or medical conditions incurable with conventional therapies.
SAVE LIFE USING CELL BASED THERAPEUTICS
Our mission is to help people with advanced cancers or life-threatening genetic disorders by bringing a cure or improve the quality of life using cell based therapeutic technologies developed through high quality scientific research.
We focused on technologies Which allow us to develop multiple pipeline of products for treating different disease conditions.
Immunotherapy
Immunotherapy is a novel mode of anti-cancer therapy.
The anti-cancer effect is mediated through patients own immune cells to fight cancer cells.
Gene-Edited Cell therapy
Recent advances in gene editing tools like Crisper-Cas9 has allowed the precise gene editing possible in the field of biology.
We plan to develop multiple products using gen-edited cells for treating cancers and genetic disorders.
Some stats
Statistics and information on cancer incidence are presented here.
Cases
Deaths
Smoking
NEWS UPDATES
U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. “We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” said FDA Commissioner Scott Gottlieb, M.D. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses. At the FDA, we’re committed to helping expedite the development and review of groundbreaking treatments that have the potential to be life-saving.”
August 30, 2017
Dr. Francis Collins
Tremendous progress continues to be made against the Emperor of All Maladies, cancer. One of the most exciting areas of progress involves immunotherapy, a treatment strategy that harnesses the natural ability of the body’s own immune cells to attack and kill tumor cells. A lot of extremely hard work has gone into this research, so I was thrilled to learn that the Food and Drug Administration (FDA) just announced today its first approval of a promising type of immunotherapy called CAR-T cell therapy for kids and young adults with B-cell acute lymphoblastic leukemia (ALL)—the most common childhood cancer in the U.S.
August 30, 2017
FDA Panel Unanimously Recommends Approval for Novartis' CAR T-Cell Therapy CTL019 by Alex Philippidis
Novartis is on track to win FDA approval later this year to market the first chimeric antigen receptor (CAR) T-cell therapy, following an advisory committee’s unanimous recommendation yesterday in favor of the company’s leukemia-fighting treatment CTL019 (tisagenlecleucel).The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 10 to 0 to recommend approval of CTL019, which is indicated for the treatment of relapsed or refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL). The FDA usually, but not always, follows the recommendations of its advisory committees.
“The panel’s support was overwhelming. One voter said this is the most exciting thing he has seen in his career. You don’t normally hear things like that at an FDA meeting and I think it is a sign of how truly promising this therapy can be,” Brad Loncar, CEO of Loncar Investments, told GEN.
July 13, 2017
